Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence